I am a
Home I AM A Search Login

Papers of the Week

Papers: 10 Feb 2024 - 16 Feb 2024

2024 Feb 15

N Engl J Med




Inhibition of CD40L with Frexalimab in Multiple Sclerosis.


Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G


The CD40-CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L monoclonal antibody being evaluated for the treatment of multiple sclerosis.